Published in ISRN Oncol on December 22, 2013
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (1994) 36.53
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (2003) 13.19
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol (2007) 7.46
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med (2005) 5.24
American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol (2010) 4.93
Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med (2005) 4.66
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 4.13
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst (2009) 3.89
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet (2000) 3.50
Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst (2001) 3.37
Massively parallel sequencing: the next big thing in genetic medicine. Am J Hum Genet (2009) 3.01
NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw (2009) 2.78
Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol (2009) 2.74
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer (2006) 2.41
Keeping up with the next generation: massively parallel sequencing in clinical diagnostics. J Mol Diagn (2008) 2.24
Genetic testing and cancer risk management recommendations by physicians for at-risk relatives. Genet Med (2011) 2.08
Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genet Med (2009) 2.05
ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gynecol (2009) 2.02
Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns (2011) 1.92
Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet (2008) 1.90
Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin (2011) 1.90
Physician use of genetic testing for cancer susceptibility: results of a national survey. Cancer Epidemiol Biomarkers Prev (2003) 1.83
Awareness and utilization of BRCA1/2 testing among U.S. primary care physicians. Am J Prev Med (2011) 1.80
Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol (2007) 1.78
Adverse events in cancer genetic testing: medical, ethical, legal, and financial implications. Cancer J (2012) 1.69
Prevention and management of hereditary breast cancer. J Clin Oncol (2005) 1.55
Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer (2005) 1.54
Reported referral for genetic counseling or BRCA 1/2 testing among United States physicians: a vignette-based study. Cancer (2011) 1.47
Errors in delivery of cancer genetics services: implications for practice. Conn Med (2010) 1.44
Identification of genetic counseling service delivery models in practice: a report from the NSGC Service Delivery Model Task Force. J Genet Couns (2013) 1.33
Physicians' experiences with BRCA1/2 testing in community settings. J Clin Oncol (2008) 1.29
Management updates for women with a BRCA1 or BRCA2 mutation. Mol Diagn Ther (2007) 1.20
Designing a patient-centered personal health record to promote preventive care. BMC Med Inform Decis Mak (2011) 1.17
Cancer risk assessment: examining the family physician's role. J Am Board Fam Med (2006) 1.15
Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet (2008) 1.12
Differences and similarities in breast cancer risk assessment models in clinical practice: which model to choose? Breast Cancer Res Treat (2008) 1.09
Further development and evaluation of a breast/ovarian cancer genetics referral screening tool. Genet Med (2010) 1.09
Extending comprehensive cancer center expertise in clinical cancer genetics and genomics to diverse communities: the power of partnership. J Natl Compr Canc Netw (2010) 1.05
Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral. Cancer Epidemiol Biomarkers Prev (2013) 1.05
Earlier age of onset of BRCA mutation-related cancers in subsequent generations. Cancer (2011) 1.05
A statewide survey of practitioners to assess knowledge and clinical practices regarding hereditary breast and ovarian cancer. Genet Test Mol Biomarkers (2013) 1.03
Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway. Clin Genet (2012) 0.98
Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers (2009) 0.96
Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control (2012) 0.93
Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nat Clin Pract Oncol (2007) 0.93
Patient and primary care provider experience using a family health history collection, risk stratification, and clinical decision support tool: a type 2 hybrid controlled implementation-effectiveness trial. BMC Fam Pract (2013) 0.91
Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Res Treat (2011) 0.90
Report from the National Society of Genetic Counselors service delivery model task force: a proposal to define models, components, and modes of referral. J Genet Couns (2012) 0.88
Evaluation of mathematical models for breast cancer risk assessment in routine clinical use. Eur J Cancer Prev (2007) 0.86
A collaborative approach to genetic testing: a community hospital's experience. J Genet Couns (2009) 0.85
Does genetic counseling have any impact on management of breast cancer risk? Genet Test (2005) 0.84
Genetic service delivery: infrastructure, assessment and information. Public Health Genomics (2012) 0.84
Management of women at increased risk for hereditary breast cancer. Breast Dis (2007) 0.81
The clinical management of BRCA1 and BRCA2 mutation carriers. Curr Oncol Rep (2008) 0.81
Ingredients for success: a familial cancer clinic in an oncology practice setting. J Oncol Pract (2011) 0.79